Tang Sicheng, Gao Pan, Chen Hanmin, Zhou Xiangyue, Ou Yibo, He Yue
Medical Clinic and Polyclinic IV, Ludwig-Maximilians-University Munich (LMU), Munich, Germany.
Department of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Front Cell Neurosci. 2020 Sep 25;14:590789. doi: 10.3389/fncel.2020.590789. eCollection 2020.
Traumatic brain injury (TBI) is a structural and physiological disruption of brain function caused by external forces. It is a major cause of death and disability for patients worldwide. TBI includes both primary and secondary impairments. Iron overload and ferroptosis highly involved in the pathophysiological process of secondary brain injury. Ferroptosis is a form of regulatory cell death, as increased iron accumulation in the brain leads to lipid peroxidation, reactive oxygen species (ROS) production, mitochondrial dysfunction and neuroinflammatory responses, resulting in cellular and neuronal damage. For this reason, eliminating factors like iron deposition and inhibiting lipid peroxidation may be a promising therapy. Iron chelators can be used to eliminate excess iron and to alleviate some of the clinical manifestations of TBI. In this review we will focus on the mechanisms of iron and ferroptosis involving the manifestations of TBI, broaden our understanding of the use of iron chelators for TBI. Through this review, we were able to better find novel clinical therapeutic directions for further TBI study.
创伤性脑损伤(TBI)是由外力导致的脑功能结构和生理紊乱。它是全球患者死亡和残疾的主要原因。TBI包括原发性和继发性损伤。铁过载和铁死亡高度参与继发性脑损伤的病理生理过程。铁死亡是一种调节性细胞死亡形式,因为大脑中铁积累增加会导致脂质过氧化、活性氧(ROS)产生、线粒体功能障碍和神经炎症反应,从而导致细胞和神经元损伤。因此,消除铁沉积等因素并抑制脂质过氧化可能是一种有前景的治疗方法。铁螯合剂可用于消除过量铁并减轻TBI的一些临床表现。在本综述中,我们将重点关注铁和铁死亡涉及TBI表现的机制,拓宽我们对铁螯合剂用于TBI的理解。通过本综述,我们能够更好地为进一步的TBI研究找到新的临床治疗方向。